Bioniq raises $15m to revolutionize personalized health with AI and blood data

Bioniq, the pioneering London-based health tech company known for its personalized supplements derived from blood biomarker data, has successfully closed its Series B funding round with an impressive $15 million. The round was led by European venture capitals HV Capital and Unbound, catapulting Bioniq’s valuation to $75 million. This strategic infusion of funds is earmarked for scaling Bioniq’s global operations, particularly focusing on expanding its footprint in the U.S. and the Middle East.

Since its inception in 2019, Bioniq has been at the forefront of transforming the dietary supplements market with its tailored nutrition solutions. The recent funding will enhance their capabilities through integrations with global laboratory networks and boost their operational, market, and human resource endeavors across critical regions. “This capital will enable us to push further into key global markets and refine our product offerings to meet the evolving health needs of our customers,” stated Vadim Fedotov, co-founder and CEO of Bioniq.

Fedotov also highlighted the shift towards personalized health optimization in nutritional supplements. “We’ve entered a new era in nutritional supplementation where one-size-fits-all solutions are simply inefficient,” he remarked. Bioniq leverages an AI-driven algorithm and a vast biochemical database to develop custom supplements that align closely with individual health goals and needs.

Bioniq offers two innovative products: Bioniq PRO and Bioniq GO. Bioniq PRO caters to high performers, integrating direct blood biomarker data to customize supplement blends. Conversely, Bioniq GO provides a more accessible option, using a detailed questionnaire to tap into the same proprietary database for personalization.

The company’s products, renowned for their high bioavailability, are Swiss-made and feature pharmaceutical-grade ingredients. The unique delivery system of prebiotic guar granules aids in maximizing nutrient absorption, setting Bioniq apart in the competitive wellness industry.

Bioniq’s success is underscored by its wide acceptance across the professional sports realm, with endorsements from top athletes like Manchester United’s Diogo Dalot and former NBA star Andrei Kirilenko. These high-profile users underscore the effectiveness and reliability of Bioniq’s personalized nutrition solutions.

David Kuczek, General Partner at HV Capital, praised Bioniq’s growth trajectory. “Bioniq’s exceptional growth is a testament to its innovative approach for high-quality personalized health solutions,” he said. The sentiment was echoed by Shravin Mittal, CEO of Unbound, who commended Bioniq’s disruptive, science-based approach to nutrition.

As Bioniq continues to expand its user base, which already spans over 60 countries, the company remains focused on its mission to redefine nutritional supplementation through technology and personalization. The additional funds will undoubtedly accelerate Bioniq’s growth trajectory, promising to enhance health outcomes for users worldwide.